This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aardema, M.J., and MacGregor, J.T., 2002, Toxicology and genetic toxicology in the new era of “toxicogenomics”: impact of “-omics” technologies. Mutation Res. 499: 13–25.
Aicher, L., Wahl, D., Arce, A., Grenet, O., and Steiner, S., 1998, New insights into cyclosporine A nephrotoxicity by proteome analysis. Electrophoresis. 11: 1998–2003.
Anderson, N.L., Esquer-Blasco, R., Richardson, F., Foxworthy, P., Eacho, P., 1996. The effects of peroxisome proliferators on protein abundance in mouse liver. Toxicol. Appl. Pharmacol. 137: 75–89.
Anderson, N.L., and Anderson, N.G., 2002, The human plasma proteome. Mol. Cell. Proteom. 1: 845–867.
Bandara, L.R., and Kennedy, S., 2002, Toxicoproteomics — a new preclinical tool. DDT 7: 411–418.
Barbaud, A., Reichert-Penetrat, S., Tréchot, P., Jacquin-Petit, M-A., Ehlinger, A. et al., 1998, The use of skin testing in the investigation of cutaneous adverse drug reactions. Br. J. Dermatol. 139: 49–58.
Boxman, I.L.A., Hensbergen, P.J., Van der Schors, R.C., Bruynzeel, D.P., Tensen, C.P., et al., 2002, Proteomic analysis of skin irritation reveals the induction of HSP27 by sodium lauryl sulphate in human skin. Br. J. Dermatol. 146: 777–785.
DeLeo, V.A., 1998, Skin testing in systemic cutaneous drug reactions. Lancet 352: 1488–1490
Eberini, I., Miller, I., Zancan, V., Bolego, C., Puglshi, L., et al., 1999. Proteins of rat serum IV. Time course of acute-phase protein expression and its modulation by indomethacine. Electrophoresis, 20: 846–853.
Edwards, I.R., and Aronson, J.K., 2000, Adverse drug reactioins: definitions, diagnosis and management. Lancet 356: 1255–1259.
Gale, E.A.M., 2001, Lessons from the glitazones: a story of drug development. Lancet 357: 1870–1875.
Hampel, D.J., Sansome, C., Sha, M., Brodsky, S., Lawson, W.E. et al., 2001, Toward proteomics in uroscopy: urinary protein profiles a radiocontrast medium administration. J. Am. Soc. Nephrol. 12: 1026–1035.
Hanash, S., 2003, Disease proteomics Nature 422: 226–232.
Holmes, E., Bonner, F and Nicholson, J.K., 1995, Comparative studies on the nephrotoxicity of 2 bromoethanamine hydrobromide in the Fisher 344 rat and he multimammate desert mouse (Mastomys natalensis) Arch Toxicol 70: 89–95.
Jain, K.K., 2001, Proteomics: delivering new routes to drug discovery — Part 2. DDT 6: 829–832.
Johnson, J.A., and Bootman, J.L., 1995, Drug-induced morbidity and mortality: a cost of illness model. Arch. Intern. Med. 155: 1949–1956.
Kaufman, D.W., and Shapiro, S., 2000, Epidemiological assessment of drug-induced disease. Lancet 356: 1339–1343.
Kennedy, S., 2001, Proteomic profiling from human samples: the body fluid alternative. Toxicol. Lett. 120: 379–384.
Lazarou, J., Pomeranz, B., Corey, P. 1998. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. JAMA, 279, 1200–1205.
Lindon, J.C., Nicholson, J.K., Holmes, E., Antti, H., Bollard, M.E., et al., 2003, Contemporary issues in toxicology. The role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 187: 137–146.
Litovitz, T.L., Klein-Schwartz, W., White, S., et al., 2001, 2000 Annual report of the American Association of poison control and toxic exposure surveillence system. Am. J. Emerg. Med. 19: 337–395.
Madoz-Gurpide, J., Wang, H., Misek, D. E., Brichory, F. & Hanash, S. M., 2001, Protein based microarrays: a tool for probing the proteome of cancer cells and tissues. Proteomics 1: 1279–1287.
Man, W.J., White, I.R., Bryand, D., Bugelski, P., Kamilleri, P., et al., 2002, Protein expression analysis of drug-medicated hepatotoxicity in the Sprague-Dawley rat. Proteomics 2: 1577–1585.
Naaby-Hansen, S., Waterfield, M.D., and Cramer, R., 2000, Proteomics — post-genomic cartography to understand gene function. TRENDS Pharmacol. Sci. 22: 376–384.
Nicholson, J.K., Connelly, J., Lindon, J.C., and Holmes, E., 2002, Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev. Drug Discov 1: 153–161.
Petricoin III, E.F., Hackett, J.L., Lesko, L.J., Puri, R.K., Gutman, S.I., et al., 2002, Medical applications of microarray technologies: a regulatory science perspective. Nature Genet. Suppl. 32: 474–479.
Petricoin, E.F. Zoon, C.K., Kohn, E.C., Barrett, J.C., and Liotta, L.A., 2002, Clinical proteomics: translating benchside promise into bedside reality. Nature Rev 1: 683–695
Pirmohamed, M., and Park, B.K., 2001, Genetic susceptibility to adverse drug reactions. TRENDS Pharmacol. Sci. 22: 298–305.
Robinson, W. H. et al., 2002, Autoantigen microarrays for multiplex characterization of autoantibody responses. Nature Med. 8: 295–301.
Roses, A.D., 2000, Pharmacogenetics and the practice of medicine. Nature 405: 857–865.
Smith, L.L., 2001, Key challenges for toxicologists in the 21st century. TRENDS Pharmacol. Sci. 22: 281–285.
Steiner, S., Witzmann, F.A., 2000. Proteomics: Applications and opportunities in preclinical drug development. Electrophoresis 21: 2099–2104.
The International SNP Map Working Group., 2001, A map of the human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature, 409: 928–933.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Wilkins, M.R. (2004). Proteomics and Adverse Drug Reactions. In: Hondermarck, H. (eds) Proteomics: Biomedical and Pharmaceutical Applications. Springer, Dordrecht. https://doi.org/10.1007/1-4020-2323-5_10
Download citation
DOI: https://doi.org/10.1007/1-4020-2323-5_10
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-2322-4
Online ISBN: 978-1-4020-2323-1
eBook Packages: Springer Book Archive